公开(公告)号：US20160235809A1

公开(公告)日：2016-08-18

申请号：US15091665

申请日：2016-04-06

申请人： The Regents of the University of California ,  Schepens Eye Research Institute

发明人： Benjamin Sullivan ,  Tannin A. Schmidt ,  David A. Sullivan

IPC分类号： A61K38/14 ,  A61K47/02 ,  A61K31/728 ,  A61K47/24 ,  A61K9/00 ,  A61K38/17

CPC分类号： A61K38/14 ,  A61K9/0048 ,  A61K9/0051 ,  A61K31/568 ,  A61K31/685 ,  A61K31/688 ,  A61K31/715 ,  A61K31/728 ,  A61K38/13 ,  A61K38/17 ,  A61K38/1709 ,  A61K38/1841 ,  A61K45/06 ,  A61K47/02 ,  A61K47/24 ,  A61K2300/00

摘要： The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.

摘要翻译： 本发明提供了一种药物组合物及其使用方法，用于治疗眼部边界缺乏症，与之相关的症状，或与眼表面相关或导致眼部边界缺陷的不良状况。 本发明的药物组合物包含悬浮在眼科可接受的平衡盐溶液中的人PRG4蛋白，润滑剂片段，同系物或同种型。 本发明的药物组合物还可以包含一种或多种选自以下的眼科学上可接受的试剂：药学上可接受的药物，所述药剂选自眼科可接受的抑制剂，赋形剂，收敛剂，血管收缩剂，润肤剂，透明质酸钠，透明质酸和表面活性磷脂 载体用于局部给药。

公开(公告)号：US09248161B2

公开(公告)日：2016-02-02

申请号：US14272634

申请日：2014-05-08

申请人： The Regents of the University of California ,  Schepens Eye Research Institute

发明人： Benjamin Sullivan ,  Tannin A. Schmidt ,  David A. Sullivan

IPC分类号： A61K38/00 ,  A61K38/17 ,  A61K9/00 ,  A61K31/568 ,  A61K31/715 ,  A61K38/13 ,  A61K38/18 ,  A61K45/06 ,  A61K31/728

CPC分类号： A61K38/14 ,  A61K9/0048 ,  A61K9/0051 ,  A61K31/568 ,  A61K31/685 ,  A61K31/688 ,  A61K31/715 ,  A61K31/728 ,  A61K38/13 ,  A61K38/17 ,  A61K38/1709 ,  A61K38/1841 ,  A61K45/06 ,  A61K47/02 ,  A61K47/24 ,  A61K2300/00

摘要： The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.

摘要翻译： 本发明提供了一种药物组合物及其使用方法，用于治疗眼部边界不足，与之相关的症状，或与眼表面相关或导致眼部边界缺陷的不期望状况。 本发明的药物组合物包含悬浮在眼科可接受的平衡盐溶液中的人PRG4蛋白，润滑剂片段，同系物或同种型。 本发明的药物组合物还可以包含一种或多种选自以下的眼科学上可接受的试剂：药学上可接受的药物，所述药剂选自眼科可接受的抑制剂，赋形剂，收敛剂，血管收缩剂，润肤剂，透明质酸钠，透明质酸和表面活性磷脂 载体用于局部给药。

公开(公告)号：US20180028598A1

公开(公告)日：2018-02-01

申请号：US15645561

申请日：2017-07-10

申请人： The Regents of the University of California ,  Schepens Eye Research Institute

发明人： Benjamin Sullivan ,  Tannin A. Schmidt ,  David A. Sullivan

IPC分类号： A61K38/14 ,  A61K9/00 ,  A61K31/688 ,  A61K31/685 ,  A61K45/06 ,  A61K38/18 ,  A61K31/728 ,  A61K47/02 ,  A61K31/568 ,  A61K31/715 ,  A61K38/13 ,  A61K47/24 ,  A61K38/17

CPC分类号： A61K38/14 ,  A61K9/0048 ,  A61K9/0051 ,  A61K31/568 ,  A61K31/685 ,  A61K31/688 ,  A61K31/715 ,  A61K31/728 ,  A61K38/13 ,  A61K38/17 ,  A61K38/1709 ,  A61K38/1841 ,  A61K45/06 ,  A61K47/02 ,  A61K47/24 ,  A61K2300/00

摘要： The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.

公开(公告)号：US20140296159A1

公开(公告)日：2014-10-02

申请号：US14272634

申请日：2014-05-08

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  SCHEPENS EYE RESEARCH INSTITUTE

发明人： Benjamin Sullivan ,  Tannin A. Schmidt ,  David A. Sullivan

IPC分类号： A61K38/17 ,  A61K45/06 ,  A61K31/728

CPC分类号： A61K38/14 ,  A61K9/0048 ,  A61K9/0051 ,  A61K31/568 ,  A61K31/685 ,  A61K31/688 ,  A61K31/715 ,  A61K31/728 ,  A61K38/13 ,  A61K38/17 ,  A61K38/1709 ,  A61K38/1841 ,  A61K45/06 ,  A61K47/02 ,  A61K47/24 ,  A61K2300/00

摘要： The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.

摘要翻译： 本发明提供了一种药物组合物及其使用方法，用于治疗眼部边界不足，与之相关的症状，或与眼表面相关或导致眼部边界缺陷的不期望状况。 本发明的药物组合物包含悬浮在眼科可接受的平衡盐溶液中的人PRG4蛋白，润滑剂片段，同系物或同种型。 本发明的药物组合物还可以包含一种或多种选自以下的眼科学上可接受的试剂：药学上可接受的药物，所述药剂选自眼科可接受的抑制剂，赋形剂，收敛剂，血管收缩剂，润肤剂，透明质酸钠，透明质酸和表面活性磷脂 载体用于局部给药。

公开(公告)号：US20210169990A9

公开(公告)日：2021-06-10

申请号：US16420361

申请日：2019-05-23

申请人： The Regents of the University of California ,  Schepens Eye Research Institute

发明人： Benjamin Sullivan ,  Tannin A. Schmidt ,  David A. Sullivan

IPC分类号： A61K38/39 ,  A61K9/08 ,  A61K9/00 ,  A61K31/728 ,  A61P27/04

摘要： The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.

公开(公告)号：US20200368328A1

公开(公告)日：2020-11-26

申请号：US16420361

申请日：2019-05-23

申请人： The Regents of the University of California ,  Schepens Eye Research Institute

发明人： Benjamin Sullivan ,  Tannin A. Schmidt ,  David A. Sullivan

IPC分类号： A61K38/39 ,  A61K9/08 ,  A61K9/00 ,  A61K31/728 ,  A61P27/04

摘要： The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.

公开(公告)号：US09730978B2

公开(公告)日：2017-08-15

申请号：US15091665

申请日：2016-04-06

申请人： The Regents of the University of California ,  Schepens Eye Research Institute

发明人： Benjamin Sullivan ,  Tannin A. Schmidt ,  David A. Sullivan

IPC分类号： A61K38/00 ,  C07K9/00 ,  A61K38/14 ,  A61K9/00 ,  A61K31/568 ,  A61K31/715 ,  A61K38/13 ,  A61K38/18 ,  A61K38/17 ,  A61K45/06 ,  A61K31/728 ,  A61K31/685 ,  A61K31/688 ,  A61K47/02 ,  A61K47/24

CPC分类号： A61K38/14 ,  A61K9/0048 ,  A61K9/0051 ,  A61K31/568 ,  A61K31/685 ,  A61K31/688 ,  A61K31/715 ,  A61K31/728 ,  A61K38/13 ,  A61K38/17 ,  A61K38/1709 ,  A61K38/1841 ,  A61K45/06 ,  A61K47/02 ,  A61K47/24 ,  A61K2300/00

摘要： The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.

公开(公告)号：US09421241B2

公开(公告)日：2016-08-23

申请号：US14831317

申请日：2015-08-20

申请人： The Regents of the University of California ,  Schepens Eye Research Institute

发明人： Benjamin Sullivan ,  Tannin A. Schmidt ,  David A. Sullivan

IPC分类号： A61K31/568 ,  A61K31/728 ,  A61K38/14 ,  A61K9/00 ,  A61K31/715 ,  A61K38/13 ,  A61K38/18 ,  A61K38/17 ,  A61K45/06 ,  A61K31/685 ,  A61K31/688

CPC分类号： A61K38/14 ,  A61K9/0048 ,  A61K9/0051 ,  A61K31/568 ,  A61K31/685 ,  A61K31/688 ,  A61K31/715 ,  A61K31/728 ,  A61K38/13 ,  A61K38/17 ,  A61K38/1709 ,  A61K38/1841 ,  A61K45/06 ,  A61K47/02 ,  A61K47/24 ,  A61K2300/00

摘要： Provided herein are ophthalmically acceptable pharmaceutical compositions comprising PRG4 or lubricant fragments and a PRG4 inducing compound. The PRG4 inducing compound in the pharmaceutical composition of the present invention upregulates PRG4 expression and localization in the ocular surface for efficient surface boundary lubrication. In some instances, pharmaceutical compositions described herein are utilized for treating ophthalmic conditions, e.g., ocular boundary deficiency and symptoms associated therewith.

摘要翻译： 本文提供了包含PRG4或润滑剂片段和PRG4诱导化合物的眼科可接受的药物组合物。 本发明的药物组合物中的PRG4诱导化合物上调PRG4在眼表面的表达和定位，以有效的表面边界润滑。 在一些情况下，本文所述的药物组合物用于治疗眼科疾病，例如眼睛边界不足和与之相关的症状。

公开(公告)号：US20160015780A1

公开(公告)日：2016-01-21

申请号：US14831317

申请日：2015-08-20

申请人： The Regents of the University of California ,  Schepens Eye Research Institute

发明人： Benjamin Sullivan ,  Tannin A. Schmidt ,  David A. Sullivan

IPC分类号： A61K38/17 ,  A61K31/728 ,  A61K45/06 ,  A61K31/688 ,  A61K9/00 ,  A61K31/568 ,  A61K31/685

CPC分类号： A61K38/14 ,  A61K9/0048 ,  A61K9/0051 ,  A61K31/568 ,  A61K31/685 ,  A61K31/688 ,  A61K31/715 ,  A61K31/728 ,  A61K38/13 ,  A61K38/17 ,  A61K38/1709 ,  A61K38/1841 ,  A61K45/06 ,  A61K47/02 ,  A61K47/24 ,  A61K2300/00

摘要： Provided herein are ophthalmically acceptable pharmaceutical compositions comprising PRG4 or lubricant fragments and a PRG4 inducing compound. The PRG4 inducing compound in the pharmaceutical composition of the present invention upregulates PRG4 expression and localization in the ocular surface for efficient surface boundary lubrication. In some instances, pharmaceutical compositions described herein are utilized for treating ophthalmic conditions, e.g., ocular boundary deficiency and symptoms associated therewith.

摘要翻译： 本文提供了包含PRG4或润滑剂片段和PRG4诱导化合物的眼科可接受的药物组合物。 本发明的药物组合物中的PRG4诱导化合物上调PRG4在眼表面的表达和定位，以有效的表面边界润滑。 在一些情况下，本文所述的药物组合物用于治疗眼科疾病，例如眼睛边界不足和与之相关的症状。

公开(公告)号：US09585936B2

公开(公告)日：2017-03-07

申请号：US14974055

申请日：2015-12-18

申请人： The Regents of the University of California ,  Schepens Eye Research Institute

发明人： Benjamin Sullivan ,  Tannin A. Schmidt ,  David A. Sullivan

IPC分类号： A61K38/00 ,  A61K38/14 ,  A61K9/00 ,  A61K31/568 ,  A61K31/715 ,  A61K38/13 ,  A61K38/18 ,  A61K38/17 ,  A61K45/06 ,  A61K31/728 ,  A61K31/685 ,  A61K31/688 ,  A61K47/02 ,  A61K47/24

CPC分类号： A61K38/14 ,  A61K9/0048 ,  A61K9/0051 ,  A61K31/568 ,  A61K31/685 ,  A61K31/688 ,  A61K31/715 ,  A61K31/728 ,  A61K38/13 ,  A61K38/17 ,  A61K38/1709 ,  A61K38/1841 ,  A61K45/06 ,  A61K47/02 ,  A61K47/24 ,  A61K2300/00

摘要： The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes discomfort at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, or a lubricating fragment thereof, suspended in an ophthalmically acceptable vehicle. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.

摘要翻译： 本发明提供了一种药物组合物及其使用方法，用于治疗眼部边界缺乏症，与之相关的症状，或与眼表面相关或引起不适的不期望状况。 本发明的药物组合物包含悬浮在眼睛可接受的载体中的人PRG4蛋白或其润滑片段。 本发明的药物组合物还可以包含一种或多种选自以下的眼科学上可接受的试剂：药学上可接受的药物，所述药剂选自眼科可接受的抑制剂，赋形剂，收敛剂，血管收缩剂，润肤剂，透明质酸钠，透明质酸和表面活性磷脂 载体用于局部给药。